Development of cardiac arrhythmias in several degenerative cardiac disorders such as heart failure is precipitated by abnormalities in intracellular calcium regulation. Recently, the identification of mutations in proteins responsible for the control of intracellular calcium has been associated with an inherited arrhythmogenic syndrome called catecholaminergic polymorphic ventricular tachycardia (CPVT). Here, we review the current knowledge about the molecular pathophysiology of CPVT and we discuss some potentially innovative strategies for controlling calcium-handling abnormalities in CPVT that may provide novel therapeutic options for affected patients.
Introduction
A great body of evidence has demonstrated that calciumhandling abnormalities play an important role in the pathophysiology of heart diseases, such as heart failure and cardiomyopathies. 1 As a consequence, the concept that a new strategy for the control of cardiac rhythm abnormalities could be developed through the modulation of the key proteins that control intracellular calcium, has raised substantial interest in the field. 2, 3 In order to move forward in this direction, it is necessary to make advances in the understanding of calcium homeostasis under normal settings as well as in disease states. Recently, the mutations identified in CPVT patients in the cardiac ryanodine receptor's gene (RyR2) and in the cardiac calsequestrin's gene (CASQ2) 4, 5 have provided an ideal substrate to test novel approaches to modulate calcium homeostasis for therapeutic purposes. In this review, we outline the current knowledge about the mechanisms by which mutations in RyR2 and in CASQ2 facilitate the development of ventricular tachyarrhythmias and cardiac arrest and we speculate on the chances of developing innovative curative strategy for calcium-associated inherited arrhythmogenic syndromes.
Intracellular calcium cycling in cardiac myocytes
The delicate balance that regulates calcium fluxes between the intracellular compartment and the extracellular space in cardiac myocytes is critical to ensure cellular viability, to preserve normal contractile function and to provide a stable heart rhythm.
During the plateau phase of the cardiac action potential, a small amount of calcium enters the cardiac myocytes through the voltage-dependent L-type calcium channels, causing calcium release into the cytosol through the RyR2 channel that is located in the membrane of the sarcoplasmic reticulum (SR). This process, called calcium-induced calcium release (CICR), 6 is the basis of cardiac excitation-contraction (E-C) coupling: it increases intracellular calcium from 100 to about 1 mM and activates the contractile apparatus.
The calcium release termination mechanisms are complex and rather controversial, there is evidence for several mechanisms: RyR adaptation, RyR inactivation, SR depletion, and luminal regulation. 7 The attainment of higher concentrations of calcium allows the activation of the contractile elements of the cardiac sarcomere and subsequently reuptake of calcium into the SR ensures relaxation. To preserve the proper function of the contractile apparatus cytosolic calcium levels are lowered by two systems: the first is represented by the calcium-pump ATPase (SERCA2) that is responsible for reuptake approximately 75% of calcium into the SR; the second mechanism is represented by the sodium-calcium exchanger (NCX) that extrudes the remaining portion of cytosolic calcium from the cytoplasm. Overall, the gating of RyR2 and its multiple accessory proteins exquisitely control cardiac E-C coupling.
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RyR2 activity is highly regulated by signalling pathways as shown in Figure 1 . Under adrenergic stimulation, beta-adrenergic receptors activate a GTP-binding protein, which stimulates adenylyl cyclase to produce cAMP, which in turn activates Protein Kinase A (PKA). This kinase phosphorylates RyR2 and other central proteins related to E-C coupling, such as phospholamban and the L-type calcium channels, thus causing gain of function of calcium cycling in cardiomyocytes in response to adrenergic activation. A cogent body of evidence has supported the view that a regulatory protein called FKBP12.6 is critical in modulating the response of RyR2 to PKA phosphorylation. [9] [10] [11] Data collected from single channel gating studies of RyR2 reconstituted in lipid bilayers and from biochemical studies suggested that FKBP12.6 stabilizes RyR2 in the closed state and that hyperphosphorylation of RyR2 at Serine 2809 by PKA causes FKBP12.6 dissociation from RyR2 increasing the open probability of RyR2. It has been suggested that enhanced FKBP12.6 dissociation from RyR2 is a central event in the pathophysiology of heart failure. Albeit attractive, this hypothesis is still highly controversial. 12, 13 More recently, several authors have stressed the importance of Ca 2þ /calmodulin-dependent protein kinase II (CaMKII) phosphorylation that also regulates RyR2 activity. 14, 15 CaMKII can phosphorylate RyR2 at Serine 2815 which activates RyR2 without interfering with FKBP12.6 binding. Recently, evidence from a phospholamban knock-out mouse model showed that both CaMKII and PKA are able to phosphorylate RyR2 with possibly distinctly different functional consequences. CaMKII appears to be able to increase calcium spark frequency directly via phosphorylation of RyR2 in the absence of increased SR calcium load while PKA-mediated effects on sparks frequency rely predominantly on elevation of SR calcium load. [16] [17] [18] It is fair to point out however that some studies showed that CaMKII mediated phosphorylation inhibits RyR2, 19, 20 the reason for discrepancies is unclear and it has been suggested it may be related to the cellular model used. 20 
Catecholaminergic polymorphic ventricular tachycardia
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited disease characterized by adrenergically mediated ventricular tachyarrhythmias leading to syncope and sudden cardiac death. The clinical presentation encompasses exercise-or emotion-induced syncopal events and a distinctive pattern of reproducible, stress-related, bidirectional VT in the absence of either structural heart disease and of prolonged QT interval ( Figure 2) . 21 Since 2001, molecular genetic studies have unveiled that CPVT results from inherited defects of intracellular calcium handling in cardiac myocytes. Two genetic variants of CPVT have been identified, one transmitted as an autosomal dominant trait caused by mutations in the gene encoding the RyR2 5 and one recessive form caused by mutations in the cardiac-specific isoform of the CASQ2. 4. Triggered activity is the electrophysiological mechanism for catecholaminergic polymorphic ventricular tachycardia
Even before the identification of the gene responsible for CPVT, the hypothesis that arrhythmias in CPVT were likely to be initiated by delayed afterdepolarizations (DADs) and triggered activity had been advanced based on the observation that the bidirectional VT observed in CPVT patients closely resembles digitalis-induced arrhythmias. 21 Accordingly, it is well appreciated that digitalis-induced intracellular calcium overload leads to activation of NCX that extrudes Ca 2þ in exchange for Na þ with a stoichiometry of 1:3 that generates a net inward current (the so-called transient inward current). The transient inward current induces DADs during the diastolic interval that may reach threshold and trigger premature ventricular beats and ventricular tachycardias by a mechanism called triggered activity.
We recently developed a conditional knock-in mouse model carrier of the RyR2 R4496C mutation presenting a phenotype that reproduces the typical bidirectional VT observed in patients ( Figure 3) . 22 This model has allowed to gain important insights in the pathophysiology of CPVT. In ventricular myocytes isolated from the heart of RyR2
R4496Cþ/2 mice, we were able to perform action potential recording and to prove that DADs develop in paced RyR2
R4496Cþ/2 myocytes even in the absence of adrenergic stimulation: such a behaviour is never observed in WT myocytes. Upon beta-adrenergic stimulation, we observed further enhancement of triggered action potentials arising from DADs ( Figure 4) 23 suggesting that triggered activity is the likely mechanism for CPVT. The role of triggered activity in the genesis of arrhythmias in CPVT has further been highlighted by observations made in other animal models of the disease such as the R176Qþ/2 knock-in mice and Casq22/2 knock-out mice. 24, 25 Recently, Paavola et al. 26 for the first time demonstrated DADs in monophasic action potential recordings in CPVT patients with RyR2 mutations. Interestingly, all the data from transgenic mice and CPVT patients support the evidence that RyR2 mutations increase susceptibility to adrenergic stimulation but they also induce abnormal electrical behaviour in resting conditions. Such an observation is important as it may explain why the treatment with beta-blockers affords only an incomplete protection from life-threatening arrhythmias in CPVT patients.
Origin of bidirectional ventricular tachycardia in catecholaminergic polymorphic ventricular tachycardia
The most typical VT observed in CPVT patients, the so-called bidirectional VT, derives its name from the fact that on surface ECG it presents an alternating QRS axis morphology with a rotation of 180 degrees of the QRS on a beat-to-beat basis. Several investigators have been attracted by the unusual morphology of the tachycardia and have investigated the propagation pattern of excitation in models of bidirectional VT in vitro. Nam et al. 27 used caffeine and isoproterenol to mimic the defective calcium homeostasis in canine wedge preparation, they observed that DAD-induced triggered activity arises most frequently in the epicardium and bidirectional VT develops as a consequence of alternation in the origin of ectopic activity between endocardial and epicardial regions.
Different results were presented by Katra et al. 28 using a canine wedge model of enhanced calcium entry: these authors demonstrated that the spontaneous calcium release originating from the endocardium has the largest amplitude and the earliest onset and is, thereby, more likely to initiate DAD-mediated triggered activity. Since it is well known that Purkinje fibres are more sensitive to calcium overload than ventricular myocytes, 29 we were intrigued by the hypothesis that bidirectional VT could be triggered by DADs originating from right and left branches of the Purkinje fibres in an alternate fashion. Recently, in collaboration with the group of Jalife, it has been possible to support this evidence using epicardial optical mapping and volume-conducted ECGs in the isolated and perfused heart of our RyR2
R4496Cþ/2 knock-in mouse model. Activation maps showed that characteristic alternating-QRS ECG pattern of bidirectional VT corresponded to epicardial breakthroughs whose origin alternated, on a beat-to-beat basis, between right and left ventricle. 30 
Molecular mechanism in catecholaminergic polymorphic ventricular tachycardia
In vitro studies (performed in lipid bilayers, HEK293 cells, HL1-cardiomyocytes) suggested that the RyR2 mutations produce a 'gain of function' and cause diastolic Ca 2þ 'leakage' from the SR at conditions of sympathetic activation 12, 31, 32 leading to intracellular calcium overload that is responsible for the development of DADs and triggered activity. Despite intensive investigations, the molecular mechanisms by which RyR2 mutations alter the physiological properties of RyR2 in CPVT to initiate such arrhythmogenic cascade remain highly controversial. 12, 23, 33 In the following sections, we will review the three leading mechanisms proposed to explain how mutations identified in CPVT patients may alter the function of RyR2. 
Reduced binding affinity of FKBP12.6 to CPVT-associated RyR2 mutations
Over the years, Marks and collaborators have supported the view that an abnormal Ca 2þ leakage through the RyR2 is present in heart failure, and it is caused by an enhanced dissociation of FKBP12.6 from RyR2. 34, 35 More recently, the same group extended this hypothesis to account for the RyR2 dysfunction observed in CPVT. 10, 32 Their studies showed that CPVT-associated RyR2 mutations (S2246L, R2474S, and R4497C) exhibited reduced binding affinity to FKBP12.6 under basal conditions and that this defect is further exaggerated after PKA phosphorylation. Subsequently, this group generated a mutant form of FKBP12.6 with serine residue 37 substituted for aspartate acid (FKBP12.6-D37S) that can bind to PKA phosphorylated RyR2 and the RyR2-S2809D mutant. 10 Intriguingly, binding of FKBP12.6-D37S to RyR2-R2474S channel rescued normal channel gating and decreased open probability. These data proposed that RyR2 mutants reduce the binding affinity of RyR2 for the regulatory protein FKBP12.6 and that this defective behaviour is further aggravated when PKA phosphorylates RyR2 in response to adrenergic stimulation causing further dissociation of FKBP12.6 and promoting Ca 2þ leakage from the SR.
Albeit this hypothesis is attractive and provides a reasonable explanation for arrhythmogenesis related to RyR2 mutations, other investigators challenged it and failed to provide supportive data from different experimental protocols. George et al. 12 found that CPVT-associated RyR2 mutant channels (S2246L, N4104K, and R4497C) have normal RyR2/FKBP12.6 interaction but an abnormally augmented response to isoproterenol and forskolin. Jiang et al. 36 revealed that phosphorylation of RyR2 by PKA does not dissociate FKBP12.6 from RyR2 mutant channels [Q4201R, I4867M, S2246L, R2474S, R176Q(T2504M), and L433P]. Recently, we compared the RyR2-FKBP12.6 association in WT and in RyR2
R4496Cþ/2 mice: Western blot analysis indicated that the relative amounts of FKBP12.6 to RyR2 found in heavy SR of the stimulated hearts was similar to that found in unstimulated controls, for both WT and RyR2
R4496Cþ/2 mice. 23 These observations indicate normal RyR2-FKBP12.6 interaction in the heart from both WT and RyR2
R4496Cþ/2 animals, and further suggest that RyR2-FKBP12.6 binding is not altered following treatment with caffeine and epinephrine. Interestingly, the FKBP12.6-RyR2 ratio in the RyR2
R4496Cþ/2 mice was higher compared with WT, suggesting higher FKBP12.6-binding affinity for RyR2 R4496C compared with WT RyR2. Alternatively, in the mutant mice, there were altered cellular FKBP12.6 levels and consequently SR levels, which could be part of a compensatory mechanism for abnormalities of mutant RyR2 channels.
The reasons for the discrepancies in the FKBP12.6-binding affinity for CPVT-associated RyR2 mutant channels observed by different groups are not clear, it is possible that they depend on differences in experimental conditions. 36,37
Defective intermolecular domain interactions in catecholaminergic polymorphic ventricular tachycardia-associated RyR2 mutations
Intermolecular interaction between discrete RyR2 domains is necessary for the proper folding of the RyR2 channel. 38 In the non-activated state, the N-terminal and central domains make close contact with several subdomains (zipping domains) that concur to stabilize and maintain the closed state of the channel. It has been proposed that RyR2 mutations may cause unzipping of these regions leading to RyR2 hyperactivation or hypersensitization that may result in Ca 2þ leak from the SR. 39 A similar mechanism has been demonstrated to underlie malignant hyperthermia and central core disease that are caused by mutations in the RyR1 isoform that is expressed in skeletal muscles. Since skeletal RyR1 and cardiac RyR2 have a high level of homology, 40 it appears plausible that domain unzipping may also occur in the cardiac Ca 2þ -release channel RyR2. 41, 42 Further data in support of the critical role of domaindomain interaction in the regulation of RyR2 function came from Oda et al., 41 who designed a synthetic peptide DPc10 corresponding to Gly2460-Pro2495 of RyR2 (located in the central domains of RyR2) as a site-directing carrier. DPc10 could induced an unzipped state of the interacting N-terminal and central domains that resulted in Ca 2þ leak through the RyR2 and facilitated cAMP-dependent hyperphosphorylation of RyR2 and FKBP12.6 dissociation from RyR2.
More interestingly, a single Arg-to-Ser mutation made in DPc10, mimicking the RyR2 mutation A2474S, abolished all of the effects that would have been produced by DPc10 ( Figure 5 ). Since this mutation seems to be located in the binding region of FKBP12.6 to RyR2, it is suggested that there might be a close mechanistic relationship between the PKA-mediated FKBP12.6 dissociation and abnormal domain-domain interactions such as that seen in the DPc10-mediated channel hypersensitization.
Recently, George et al. 43 using high-resolution confocal microscopy and fluorescence resonance energy transfer analysis, provided the first cell-based evidence to support the hypothesis that SCD-linked mutations occurring in the central domain (S2246L) and the C-terminal domain (N4104K and R4497C) directly cause RyR2 channel instability via defective interdomain interaction, resulting in Ca 2þ release dysfunction. The same authors, using noise analysis, a powerful tool to elucidate mechanistically relevant information in the amplitude patterning of experimental traces, demonstrated that there are differences in the precise mode of Ca 2þ release dysfunction and conformational instability arising from central or C-terminal domain mutations. According to this hypothesis, C-terminal domain mutations exhibit postactivation channel instability that is not present in the mutations located in the central domain of RyR2. These findings support the view that abnormal interdomain interaction is a fundamental event in RyR2-mediated arrhythmogenesis and suggest that the mutation-site may be an important determinant of RyR2 channel dysfunction. In addition, this new evidence introduces the view that FKBP12.6 dissociation from RyR2 may be a consequence rather than the cause of RyR2 instability. þ activation of RyR2 and CPVT, and referred to this process with the term 'enhanced store overload-induced calcium release' (SOICR). These authors used HEK293 cell lines stably expressing the CPVT RyR2 mutants, N4104K, R4496C, and N4895D and demonstrated that they exhibit a reduced threshold for SOICR. They also showed that these RyR2 mutations increase the sensitivity of single RyR2 channels to luminal calcium dependent activation and enhanced the basal level of [3H]ryanodine binding. Subsequently, this group confirmed and extended this hypothesis to six other RyR2 mutations located in different regions of the channel [Q4201R, I4867M, S2246L, R2474, R176Q(T2504M), and L433P] and demonstrated that HEK cell lines and HL-1 cardiac cells expressing these CPVT RyR2 mutants all exhibited increased SOICR activity. 36 Single channel analyses revealed that disease-linked RyR2 mutations primarily increase the channel sensitivity to luminal calcium, but not to cytosolic calcium. These findings lead to the hypothesis that RyR2 mutations may weaken the domain-domain interactions that stabilize the channel, facilitating the conformational changes induced by binding of calcium to the luminal calcium sensor, enhancing luminal calcium activation, and reducing the threshold for SOICR.
Enhanced

CASQ2-related catecholaminergic polymorphic ventricular tachycardia
The CASQ2 protein serves as the major Ca 2þ reservoir within the SR of cardiac myocytes and is part of a protein complex that contains the ryanodine receptor. 47 Given that despite of 50% loss of CASQ2 (i.e. in heterozygous carriers) a normal clinical phenotype is observed, it is suggested that the CASQ2-related Ca 2þ buffering process can tolerate major functional impairment. Since the CASQ2-related recessive variant of CPVT is relatively uncommon, 48 only few CASQ2 mutations have been identified and functionally characterized in vitro. These studies have shown that some CASQ2 mutations impair SR Ca 2þ storing and reduce the Ca 2þ buffering capacity, 49, 50 whereas others may disrupt CASQ2-RyR2 interaction and impair the luminal calcium-dependent RyR2 regulation. 51 We recently reported the first CPVT patient carrier of two distinct CASQ2 mutations thus demonstrating that also compound heterozygous mutations cause catecholaminergic VT phenotype. More recently, Dirksen et al. 52 developed a cardiac-specific expression of the CASQ2 D307H transgene mouse model (a mutation discovered in CPVT patients), they demonstrated that CASQ2 D307H mutation impairs myocyte Ca 2þ handling and predisposes the transgenic mice to complex ventricular arrhythmias under beta-adrenergic stimulation. This transgenic mouse model for the first time establishes a causal link between CASQ2 mutation and the CPVT phenotype. These findings suggest that genetic defects of CASQ2 identified in CPVT patients can enhance responsiveness of RyR2 to luminal calcium generating diastolic calcium transients, DADs, and triggered action potentials. In this respect, both the autosomal dominant RyR2-related and the autosomal recessive CASQ2-related variants of CPVT not only have a superimposable clinical phenotype but also share a common electrophysiological mechanism represented by DADs mediated triggered activity.
Novel molecular targets for treating catecholaminergic polymorphic ventricular tachycardia
The most important result of fundamental research applied to genetic diseases is that of providing novel insights for the development of gene specific treatment of the affected patients. Such an effort has been applied to long QT syndrome and has provided some encouraging results. 53, 54 It is expected that in a severe disease such as CPVT, in which current treatment remains plagued by a high recurrence rate of life-threatening arrhythmias, novel hope for patients will come from the growing understanding of the pathophysiology of the disease. Here we will outline some of the novel therapeutic strategies that may be derived by the results of in vitro characterization of mutants and by transgenic knock-in mouse models.
Preventing triggering factors
The evidence that CPVT is triggered by an increase of the adrenergic tone and reflexes such as exercise or emotional stress, provided a clinical rationale for the use of beta-adrenergic blockers well before the causes of the disease were known. In the initial clinical observations, beta-adrenergic blockers appeared to be able to prevent the occurrence of cardiac events in CPVT patients; 21 however, incomplete protection from sudden cardiac death has been subsequently reported. It is our experience that over a long follow up at least 30% of patients develop sustained ventricular tachyarrhythmias despite compliance to therapy. 55 It is common practice to consider these individual candidates for an ICD, however given the young age of the patients, it would certainly be important to have other pharmacological options available.
Restoring the binding affinity of FKBP12.6 for RyR2
According to the hypothesis proposed by Marks and debated by other authors, 12, 23, 33 abnormal FKBP12.6-RyR2 interaction may be central in the pathogenesis of CPVT. 10, 32, 56 As discussed in a previous section of this review, Marks' group proposed the use of a 1,4-benzothiazepine derivative called JTV 519 (more recently renamed K201) to enhance the binding of FKBP12.6 to RyR2 and prevent adrenergically induced arrhythmias and sudden death. 9 Although we were unable to confirm the validity of this approach in our knock-in animal model, 23 the possibility that CPVT associated with other mutations may respond positively to the drug remains open.
Reducing ryanodine receptor open probability
As discussed earlier, calcium fluxes between cellular compartment and extracellular space must maintain a delicate balance both at rest and during adrenergic activation. It appears logical to hypothesize that reducing RyR2 open probability may be a straightforward strategy to counter the development of diastolic calcium leak and DADs. However, it may be complex to achieve this goal without interfering with normal systolic calcium release. This challenge has been successfully addressed by Venetucci et al. 45 who studied rat ventricular myocytes exposed to isoproterenol in which diastolic calcium release was induced. Application of tetracaine (50 mmol/L), a local anaesthetic that beside blocking I Na is also able to reduce RyR2 open probability, abolished the diastolic calcium release. Surprisingly, this was accompanied by an increase in the amplitude and duration of the systolic calcium transients. These data suggest that reducing ryanodine receptor open probability without altering systolic function may provide a successful antiarrhythmic strategy in CPVT.
Another drug that has been suggested to reduce RyR2 open probability is the calcium channel blocker verapamil: 57 its role in the prevention of RyR2 mediated arrhythmias is unclear. Swan et al. 58 reported that verapamil can suppress premature ventricular complexes and non-sustained ventricular salvoes in the CPVT patients with RyR2 mutation. Our experience however has been less favourable: although verapamil reduced arrhythmias in CPVT patients during exercise stress test, it was ineffective in preventing recurrence of life threatening arrhythmias at follow up. Whether the concentration of the drug administered at therapeutic dosages is able to affect RyR2 open probability is unknown: systematic investigations on the role of verapamil in CPVT is warranted.
Blocking sodium-calcium exchanger
Intracellular calcium overload can activate NCX that by exchanging one Ca 2þ for three Na þ generating a net inward current leading to triggered arrhythmias in CPVT: it may be therefore reasonable to explore NCX as a therapeutic target in CPVT. Since the selective blockade of NCX may increase calcium load of the cell, it may be important to consider the use of NCX blockers with a broader action including blockade of L-type calcium channel. 59 No data are available so far to allow speculations on the efficacy of this approach in CPVT.
Modulation of CAMKII mediated phosphorylation of RyR2
In our own knock-in mouse model, we demonstrated that inhibition of CaMKII by KN93 (a selective blocker of CaMKII) is highly effective in preventing adrenergically mediated arrhythmias in vivo and the development of DADs in vitro. 54 These data suggest that modulation of CaMKII may represent a novel therapeutic strategy for CPVT.
conclusions
In the last few years, investigations directed to the understanding of CPVT, an arrhythmogenic disorder caused by mutations in the cardiac ryanodine receptor, and in the SR calcium buffering protein calsequestrin have given momentum to the study of the regulation of intracellular calcium handling. Albeit several questions on the pathophysiology of CPVT still remain highly disputed, it is clear that the collaboration between clinical scientists and basic researchers has provided intriguing speculations about the electrophysiologic mechanisms leading to sudden death in CPVT. Interestingly, the development of knock-in animal models of CPVT has created a novel substrate suitable to advance not only the clinical field but also to promote the basic understanding of arrhythmogenesis related to intracellular calcium dysregulation. It is expected that these research effort will concur to the development of new treatment for the prevention of life-threatening arrhythmias in CPVT young patients. 
